Weekly Recap | Editas Medicine -16.41%, consensus target above spotWeekly Review·Sep 12, 2026 at 08:10 AMEDIT-3.61%
The Nasdaq Biotechnology Index fell by 2%. Among the constituent stocks, Jyong Biotech dropped by 20.95%, BridgeBio Pharma fell by 15.21%, Sionna Therapeutics decreased by 15.12%, Abcellera Biologics declined by 14.98%, and Editas Medicine fell by 14.62%. Gilead Sciences rose by 2.15%, Silence Therapeutics increased by 5.12%, Erasca went up by 5.69%, and Phibro Animal Health surged by 22.02%Wallstreetcn·Feb 5, 2026 at 11:56 PMXLV-1.11%ARKG+0.61%
The Nasdaq Biotechnology Index rose by more than 2.4%. Among them, Editas Medicine increased by 34.72%, Arcturus Therapeutics Holdings Inc. rose by 29.01%, and Stoke Therapeutics climbed by 24.98%. In contrast, Pliant fell by 6.25%, Autolus Therapeutics dropped by 14.62%, and Zevra Therapeutics decreased by 19.81%Wallstreetcn·Aug 13, 2025 at 08:56 PMSTOK-2.57%ARCT-8.29%
The Nasdaq Biotechnology Index rose by 1.3%, temporarily outperforming the three major U.S. stock indicesWallstreetcn·Jul 2, 2025 at 02:11 PMPGEN-3.13%PRME-1.61%
